Discovery May Offer Way Around Hormone Therapy Resistance in Prostate Cancer

Discovery May Offer Way Around Hormone Therapy Resistance in Prostate Cancer
A late-stage prostate cancer therapy, being developed by a company founded by researchers at Purdue University, may help to improve outcomes for patients by working to overcome the resistance they often develop to hormone therapy. Prostate cancer depends on the male sex hormone, testosterone, to grow. Hormone therapy, which blocks the production of these hormones (androgens), or their ability to bind to specific androgen receptors, is often used to lower the risk of an early prostate cancer coming back after treatment, and to shrink advanced prostate tumors. "Hormone therapies have a goal to reduce male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells," Ji-Xin Cheng, a professor in biomedical engineering at Purdue University with experience in cancer biology and pharmaceutical development, said in a news release. But one of the main challenges that patients face is resistance to hormone treatments. The researchers' treatment approach consists in targeting cholesterol metabolism instead of the androgen pathway. "Almost 100 percent of cancer patients will eventually develop a resistance to hormone therapies," Cheng said. "Every year in the United States around 32,000 new [prostate] cancer cases become resistant, lessening the likelihood of survival." Cheng founded the startup, Resarci Therapeutics, alon
Subscribe or to access all post and page content.

One comment

  1. Romeao Jennings says:

    I have had metastatic small cell prostate cancer since 1998. I have been through all treatments and now running out of options. How do I get on the list to test this new therapy? PSA is now around 300. I have been resistant for about 4 years now.

Leave a Comment

Your email address will not be published. Required fields are marked *